RxDoctor Payments DataLook up a doctor →

Mitchell Cabisudo, MD

Child & Adolescent Psychiatry · New Windsor, NYNPI 1801055561

Payments from drug & device makers

$346,209in general payments, 2019–2025

Across 864 payments — averaging $400.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$241K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$95K
  • Supernus Pharmaceuticals, Inc.$3K
  • Johnson & Johnson$2K
  • Alkermes, Inc.$1K
  • Corium, LLC$582
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$7,3002%
  • Speaking & faculty fees$261,10075%
  • Travel & lodging$59,69717%
  • Food & beverage$18,0465%
  • Education$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$346,209 in reported general payments places this provider in the 95th percentile of 317 child & adolescent psychiatry providers in New York.

See all child & adolescent psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$337,604
Medicare patients
215
Services billed
2,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate20$39,077
Aripiprazole28$745
Trazodone Hcl38$619
Ziprasidone Hcl20$473
Prazosin Hcl18$411
Duloxetine Hcl40$370
Clonazepam36$356
Bupropion XlBupropion Hcl17$325
Alprazolam37$282
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$231
Sertraline Hcl14$219
Divalproex Sodium ErDivalproex Sodium13$186
Lamotrigine35$128
Escitalopram Oxalate15$94
Fluoxetine Hcl13$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$95,458$39,07720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 child & adolescent psychiatry providers in New York.

Other child & adolescent psychiatry in New Windsor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →